Observations of second primary malignancy in patients with multiple myeloma

Anne Ormerod, Christopher A. Fausel, Rafat Abonour, Patrick J. Kiel

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Advances in the treatment of multiple myeloma have resulted in immunomodulatory (IMiD) agents becoming integral to the standard treatment armamentarium. IMiD agents are effective in the initial and relapsed settings of multiple myeloma. Three studies evaluating the duration of remission in maintenance lenalidomide vs. placebo reported an increased incidence of second primary malignancies in patients receiving maintenance therapy. The purpose of this study was to evaluate the incidence of second primary malignancies after IMiD exposure for standard induction and relapsed therapy in myeloma. Patients and Methods: A retrospective chart review was conducted at the Indiana University Simon Cancer Center in Indianapolis, Indiana. Patients were older than 18 years and had been diagnosed with multiple myeloma. Patients with a previous diagnosis of cancer were excluded. The primary objective was to assess the incidence of second primary malignancies in all patients. Secondary objectives included the type of malignancy, whether patients had been previously treated with IMiD therapy and the time from treatment initiation to diagnosis of a second malignancy. Results: Three hundred twenty-five patients were reviewed and 279 were included in the study. Ten patients were diagnosed with a second primary malignancy (3.5%). Nine of the 10 patients were treated with IMiD therapy before diagnosis (P = .169). The mean time to diagnosis was 360 days for all patients. Conclusion: The incidence of second primary malignancy was not statistically significant in the IMiD-treated patients. Further long-term follow-up is needed to better assess the potential adverse events of these novel agents.

Original languageEnglish
Pages (from-to)113-117
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume12
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Second Primary Neoplasms
Multiple Myeloma
Incidence
Therapeutics
Neoplasms
Placebos
Maintenance

Keywords

  • Immunomodulatory agents
  • Lenalidomide
  • Second primary malignancy
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Observations of second primary malignancy in patients with multiple myeloma. / Ormerod, Anne; Fausel, Christopher A.; Abonour, Rafat; Kiel, Patrick J.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 12, No. 2, 04.2012, p. 113-117.

Research output: Contribution to journalArticle

Ormerod, Anne ; Fausel, Christopher A. ; Abonour, Rafat ; Kiel, Patrick J. / Observations of second primary malignancy in patients with multiple myeloma. In: Clinical Lymphoma, Myeloma and Leukemia. 2012 ; Vol. 12, No. 2. pp. 113-117.
@article{bcbbd8429081415081e4b067a318e2c6,
title = "Observations of second primary malignancy in patients with multiple myeloma",
abstract = "Background: Advances in the treatment of multiple myeloma have resulted in immunomodulatory (IMiD) agents becoming integral to the standard treatment armamentarium. IMiD agents are effective in the initial and relapsed settings of multiple myeloma. Three studies evaluating the duration of remission in maintenance lenalidomide vs. placebo reported an increased incidence of second primary malignancies in patients receiving maintenance therapy. The purpose of this study was to evaluate the incidence of second primary malignancies after IMiD exposure for standard induction and relapsed therapy in myeloma. Patients and Methods: A retrospective chart review was conducted at the Indiana University Simon Cancer Center in Indianapolis, Indiana. Patients were older than 18 years and had been diagnosed with multiple myeloma. Patients with a previous diagnosis of cancer were excluded. The primary objective was to assess the incidence of second primary malignancies in all patients. Secondary objectives included the type of malignancy, whether patients had been previously treated with IMiD therapy and the time from treatment initiation to diagnosis of a second malignancy. Results: Three hundred twenty-five patients were reviewed and 279 were included in the study. Ten patients were diagnosed with a second primary malignancy (3.5{\%}). Nine of the 10 patients were treated with IMiD therapy before diagnosis (P = .169). The mean time to diagnosis was 360 days for all patients. Conclusion: The incidence of second primary malignancy was not statistically significant in the IMiD-treated patients. Further long-term follow-up is needed to better assess the potential adverse events of these novel agents.",
keywords = "Immunomodulatory agents, Lenalidomide, Second primary malignancy, Thalidomide",
author = "Anne Ormerod and Fausel, {Christopher A.} and Rafat Abonour and Kiel, {Patrick J.}",
year = "2012",
month = "4",
doi = "10.1016/j.clml.2011.11.003",
language = "English",
volume = "12",
pages = "113--117",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Observations of second primary malignancy in patients with multiple myeloma

AU - Ormerod, Anne

AU - Fausel, Christopher A.

AU - Abonour, Rafat

AU - Kiel, Patrick J.

PY - 2012/4

Y1 - 2012/4

N2 - Background: Advances in the treatment of multiple myeloma have resulted in immunomodulatory (IMiD) agents becoming integral to the standard treatment armamentarium. IMiD agents are effective in the initial and relapsed settings of multiple myeloma. Three studies evaluating the duration of remission in maintenance lenalidomide vs. placebo reported an increased incidence of second primary malignancies in patients receiving maintenance therapy. The purpose of this study was to evaluate the incidence of second primary malignancies after IMiD exposure for standard induction and relapsed therapy in myeloma. Patients and Methods: A retrospective chart review was conducted at the Indiana University Simon Cancer Center in Indianapolis, Indiana. Patients were older than 18 years and had been diagnosed with multiple myeloma. Patients with a previous diagnosis of cancer were excluded. The primary objective was to assess the incidence of second primary malignancies in all patients. Secondary objectives included the type of malignancy, whether patients had been previously treated with IMiD therapy and the time from treatment initiation to diagnosis of a second malignancy. Results: Three hundred twenty-five patients were reviewed and 279 were included in the study. Ten patients were diagnosed with a second primary malignancy (3.5%). Nine of the 10 patients were treated with IMiD therapy before diagnosis (P = .169). The mean time to diagnosis was 360 days for all patients. Conclusion: The incidence of second primary malignancy was not statistically significant in the IMiD-treated patients. Further long-term follow-up is needed to better assess the potential adverse events of these novel agents.

AB - Background: Advances in the treatment of multiple myeloma have resulted in immunomodulatory (IMiD) agents becoming integral to the standard treatment armamentarium. IMiD agents are effective in the initial and relapsed settings of multiple myeloma. Three studies evaluating the duration of remission in maintenance lenalidomide vs. placebo reported an increased incidence of second primary malignancies in patients receiving maintenance therapy. The purpose of this study was to evaluate the incidence of second primary malignancies after IMiD exposure for standard induction and relapsed therapy in myeloma. Patients and Methods: A retrospective chart review was conducted at the Indiana University Simon Cancer Center in Indianapolis, Indiana. Patients were older than 18 years and had been diagnosed with multiple myeloma. Patients with a previous diagnosis of cancer were excluded. The primary objective was to assess the incidence of second primary malignancies in all patients. Secondary objectives included the type of malignancy, whether patients had been previously treated with IMiD therapy and the time from treatment initiation to diagnosis of a second malignancy. Results: Three hundred twenty-five patients were reviewed and 279 were included in the study. Ten patients were diagnosed with a second primary malignancy (3.5%). Nine of the 10 patients were treated with IMiD therapy before diagnosis (P = .169). The mean time to diagnosis was 360 days for all patients. Conclusion: The incidence of second primary malignancy was not statistically significant in the IMiD-treated patients. Further long-term follow-up is needed to better assess the potential adverse events of these novel agents.

KW - Immunomodulatory agents

KW - Lenalidomide

KW - Second primary malignancy

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84858978343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858978343&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2011.11.003

DO - 10.1016/j.clml.2011.11.003

M3 - Article

C2 - 22178548

AN - SCOPUS:84858978343

VL - 12

SP - 113

EP - 117

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 2

ER -